THE CLINICAL PROFILES OF AVIAN INFLUENzA IN ENDEMIC AND NON-ENDEMIC REGIONS IN INDONESIA. HOSPITAL-BASED STUDIES AND ITS IMPLICATION ON CLINICAL MANAGEMENT IN THE FUTURE
Downloads
Indonesia is a greatest burden country of H5N1 avian influenza (AI) virus infection in the world, since first outbreak in Central Java 2005 until August 2010 there was 168 confirmed cases and 138 dead cases. The incidence increasing rapidly in widespread area endemic in Java, Sumatera, Bali and Sulawesi, and sporadic outbreaks in other areas. The World Health Organization stated that AI still became a treat in the next pandemic. H5N1 AI virus infection spreads in almost all provinces, but its endemic in Jakarta, Tangerang and Banten and in other area such Surabaya, Bali were sporadic outbreaks. There are 27 confirmed H5N1 AI infection cases in Jakarta from 296 suspected cases, while in Surabaya only 5 confirmed H5N1 AI infection cases from 12 suspected cases. The age of patient mean with H5N1 AI infection was 16.9 ± 11.6 yo in Jakarta and 24 ± 8.51 yo in Surabaya. There was no difference between male and female. Mortality rate was 77.7% in Jakarta and 60% in Surabaya. A large number of case has indirect contact history, predominantly by visiting market or areas where outbreaks of poultry disease. The clinical feature H5N1 AI virus infection could manifest as mild until severe pneumonia that often progress rapidly to ARDS. In Jakarta, 74% case showed abnormality chest radiography as bilateral pneumonia, while in Surabaya showed lobar pneumonia and bilateral pneumonia. Management patient of H5N1 AI infection is supportive therapy and antiviral, whereas a large number of cases needed mechanical ventilator support.
2. The Writing Committee of WHO consultation on human influenza
A/H5, Avian Influenza A (H5N1) Infection in Humans. N Engl JMed
2005; 353: 1874–85.
3. The Writing Committee of WHO consultation on human influenza
A/H5, Update on Avian Influenza A (H5N1) Infection in Humans.
N Engl JMed 2008; 358: 261–73.
4. Schultsz C, Dong VC, Chau NVV, et al. Avian influenza H5N1 and healthcare workers. Emerg Infect Dis 2005; 11: 1158–9.
5. World Health Organization. Avian influenza ” situation in Indonesia” update 16. 2010. (Accessed August 20, 2010, at http://www.who.int/csr/don/2010_08_04/en/print.html.)
6. Sumiarto B, Arifin B, Overview on Poultry Sector and HPAI Situation for Indonesia with Special Emphasis on the Island of Java, 2007 available access on http://www.hpai-research.net/index.html.
7. Sardikin et al, Clinical and Epidemiological Features of Patients With Confirmed Avian Influenza Presenting to Sulianti Saroso Infectious Diseases Hospital, Indonesia, 2005–2007, Ann Acad Med Singapore 2008; 37: 454–7.
8. de Jong MD, Cam BV, Qui PT, et al. Fatal Avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005; 352: 686–91.
9. To KF, Chan PK, Chan KF, et al. Pathology of fatal human infection associated with avian influenza A H5N1 virus. J Med Virol 2001; 63:242–6.
10. Annual report database patient H5N1 AI Infection in Dr. Soeotomo Hospital.
11. World Health Organization. WHO interim guidelines on clinical
management of humans infected by influenza A(H5N1). February
20, 2004.
12. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may
determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005; 192: 665–72.
13. Frederick G, Hayden, Antiviral Resistance in Influenza Viruses –
Implications for Management nad Pandemic Response. N Engl J
Med 2006; 354: 785–8.
14. World Health Organization. Summary of the second WHO
consultation on clinical aspects of human infection with avian
influenza A (H5N1) virus. (Accessed August 20, 2010, at http://www.
who.int/csr/ disease/avian_influenza/meeting19_03_ 2007/en/index.
html.)
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
